Pharmavitae Analytics explores Shionogi’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2016-26.
- 2021 outlook - Shionogi will add over $300m in revenue out to 2021 as it expands its market share in HIV.
- 2026 outlook - The company will experience minimal growth out to 2026 as mid-term growth is offset by patent expiries.
- Events - The expansion of the HIV franchise and CNS portfolio will offset the continued erosion of Crestor.
- Shionogi’s prescription pharmaceutical sales are forecast to achieve modest growth.
- Shionogi’s CNS portfolio will be a major contributor to sales growth.
- New products Tivicay and Triumeq will be the key driver for Shionogi.
- Symproic launch in the US and Japan
- Analysis structure
- How is Shionogi strategically poised out to 2026?
- What are Shionogi’s key strengths, weaknesses, opportunities, and threats?
- What are Shionogi’s key catalysts over the next four quarters?
- What is Shionogi’s forecasted sales performance out to 2026?
- What is the revenue trajectory of Shionogi’s current top 10 products out to 2026?
- Which therapy areas will experience the largest growth and decline?
- What are the portfolio weightings of Shionogi based on the lifecycle of products?
- Why will specific therapy areas experience the largest growth and decline?
- What are the detailed competitive dynamics at play in Shionogi’s important therapeutic markets?
- How is Shionogi adapting strategically to internal and external headwinds?
- Crestor cliff
- Shionogi growth strategy
- Licensing efforts
- Shionogi’s SWOT analysis
- Shionogi’s key events and catalysts
- Shionogi’s prescription pharma sales outlook
- Shionogi’s therapy area dynamics
- Shionogi’s top 10 products over 2016-26
- Shionogi’s launch/core/expiry analysis
- Shionogi’s financial outlook
- Shionogi’s M&A history
- Central nervous system
- Infectious diseases
List of Figures
Figure 1: Shionogi’s prescription pharmaceutical sales ($m) and growth rate (%), 2013-26
Figure 2: Shionogi’s therapy area dynamics, 2016-26
Figure 3: Shionogi’s top 10 product sales ($m), 2016-26
Figure 4: Shionogi’s launch/core/expiry analysis, 2016-26
Figure 5: Shionogi’s operating revenue/cost analysis ($m), 2010-22
List of Tables
Table 1: Shionogi’s sales by therapy area ($m), 2016-26
Table 2: Shionogi’s growth drivers and resistors
Table 3: Shionogi’s sales by launch, core, and expiry portfolio ($m), 2016-26
Table 4: Shionogi’s financial performance, 2015-22
Table 5: Shionogi’s key merger and acquisition deals, 2003-16
Table 6: Shionogi’s metabolic portfolio ($m), 2016-26
Table 7: Shionogi’s central nervous system portfolio ($m), 2016-26
Table 8: Shionogi’s infectious diseases portfolio ($m), 2016-26
Table 9: Shionogi’s genitourinary portfolio ($m), 2016-26